Home > Publications Database > Mind Diet Adherence and Cognitive Performance in the Framingham Heart Study. > print

001     162628
005     20240320113535.0
024 7 _ |a 10.3233/JAD-201238
|2 doi
024 7 _ |a pmid:34092629
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
024 7 _ |a altmetric:107154011
|2 altmetric
037 _ _ |a DZNE-2021-01324
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Melo van Lent, Debora
|0 P:(DE-2719)2811697
|b 0
|e First author
|u dzne
245 _ _ |a Mind Diet Adherence and Cognitive Performance in the Framingham Heart Study.
260 _ _ |a Amsterdam
|c 2021
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710930897_2064
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Adherence to the Mediterranean-DASH for Neurodegenerative Delay (MIND) diet has previously been associated with cognitive decline and dementia. To our knowledge, no prior study has investigated the association between the MIND diet and measures of brain volume, silent brain infarcts (SBIs), or brain atrophy.We evaluated whether adherence to the MIND diet associated with superior cognitive function, larger brain volumes, fewer SBIs, and less cognitive decline in the community-based Framingham Heart Study.2,092 participants (mean±SD, age 61±9) completed Food Frequency Questionnaires, averaged across a maximum of 3-time points (examination cycles 5, 6, and 7), cognitive testing at examination cycle 7 (present study baseline: 1998-2001) and after a mean±SD of 6.6±1.1 years from baseline (n = 1,584). A subset of participants also completed brain magnetic resonance imaging (MRI) at examination cycle 7 (n = 1,904). In addition, participants with dementia, stroke, and other relevant neurological diseases such as significant head trauma, subdural hematoma, or multiple sclerosis were excluded from the analyses.Higher MIND diet scores were associated with better global cognitive function (β±SE,+0.03SD±0.01; p = 0.004), verbal memory, visual memory, processing speed, verbal comprehension/reasoning, and with larger total brain volume (TBV) following adjustments for clinical, lifestyle and demographic covariates, but not with other brain MRI measures (i.e., hippocampal volume, lateral ventricular volume, white matter hyperintensity volume, and SBIs) or cognitive decline.Higher MIND diet scores associated with better cognitive performance and larger TBV at baseline, but not with cognitive decline. Clinical trials are needed to ascertain whether adopting the MIND diet affects trajectories of cognitive decline.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Apolipoprotein ɛ4
|2 Other
650 _ 7 |a MIND diet
|2 Other
650 _ 7 |a brain volume
|2 Other
650 _ 7 |a cognition
|2 Other
650 _ 7 |a dietary pattern
|2 Other
650 _ 7 |a framingham heart study
|2 Other
650 _ 7 |a silent brain infarcts
|2 Other
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Asymptomatic Diseases
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Brain Infarction: diagnosis
|2 MeSH
650 _ 2 |a Brain Infarction: epidemiology
|2 MeSH
650 _ 2 |a Cognition: physiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: epidemiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: prevention & control
|2 MeSH
650 _ 2 |a Diet, Mediterranean: psychology
|2 MeSH
650 _ 2 |a Diet, Mediterranean: statistics & numerical data
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Organ Size
|2 MeSH
650 _ 2 |a Patient Compliance: psychology
|2 MeSH
650 _ 2 |a Patient Compliance: statistics & numerical data
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
700 1 _ |a O'Donnell, Adrienne
|b 1
700 1 _ |a Beiser, Alexa S
|b 2
700 1 _ |a Vasan, Ramachandran S
|b 3
700 1 _ |a DeCarli, Charles S
|b 4
700 1 _ |a Scarmeas, Nikolaos
|b 5
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 6
|u dzne
700 1 _ |a Jacques, Paul F
|b 7
700 1 _ |a Seshadri, Sudha
|b 8
700 1 _ |a Himali, Jayandra J
|b 9
700 1 _ |a Pase, Matthew P
|b 10
773 _ _ |a 10.3233/JAD-201238
|g Vol. 82, no. 2, p. 827 - 839
|0 PERI:(DE-600)2070772-1
|n 2
|p 827 - 839
|t Journal of Alzheimer's disease
|v 82
|y 2021
|x 1875-8908
856 4 _ |u https://pub.dzne.de/record/162628/files/DZNE-2021-01324_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/162628/files/DZNE-2021-01324_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:162628
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2811697
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2000057
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 0
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Patient Studies
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21